Prosecution Insights
Last updated: August 18, 2026

Mesoblast International Sárl

11 pending office actions • 6 art units • 9 examiners • 0 of 11 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days

Portfolio Summary

11
Total Pending OAs
7
Non-Final OAs
4
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

3
Overdue
1
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (3)Due ≤ 7 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

7
Hard (64%)
4
Medium (36%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only3 (27%)
Double-patenting + other1 (9%)
Multi-statute (no §101)7 (64%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

10
Life Sciences
91% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
1
Business / Other
9% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

110 h
Manual time on pending OAs
22 h
Time saved (low, 20%)
38 h
Time saved (mid, 35%)
1.0 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
THUESON, HANNA MARIE 2 77.3% +26.5%
KIM, TAEYOON 2 51.6% +51.8%
TIWARI, VYOMA SHUBHAM 1 30.2% +46.7%
GU, QINHUA 1 77.3% +27.6%
MARVICH, MARIA 1 54.7% +28.1%
SHIBUYA, MARK LANCE 1 32.3% +24.9%
CONNORS, ALEXANDRA F 1 23.1% +44.3%
TAKENAKA, RISA 1 28.6% +100.0%
BARRON, SEAN C 1 53.3% +30.6%

Hard Cases (8)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18041303 A COMPOSITION COMPRISING MESENCHYMAL PRECURSOR OR STEM CELLS AND THEIR USE KIM, TAEYOON 18d overdue
18001462 3D CULTURE OF MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS SHIBUYA, MARK LANCE 17d overdue
17906160 METHOD FOR TREATING INFLAMMATORY BOWEL DISEASE I KIM, TAEYOON 6d
18723204 METHOD OF TREATING SEVERE GRAFT VERSUS HOST DISEASE TIWARI, VYOMA SHUBHAM
18556827 METHOD FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN SPECIFIC PATIENTS USING MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS THUESON, HANNA MARIE
18556845 METHOD FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) USING MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS THUESON, HANNA MARIE
17906150 METHOD FOR TREATING INFLAMMATORY BOWEL DISEASE II CONNORS, ALEXANDRA F
17904581 METHOD FOR TREATING CHRONIC GRAFT VERSUS HOST DISEASE TAKENAKA, RISA

Interview Candidates (11)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18041303 A COMPOSITION COMPRISING MESENCHYMAL PRECURSOR OR STEM CELLS AND THEIR USE KIM, TAEYOON 18d overdue
18001462 3D CULTURE OF MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS SHIBUYA, MARK LANCE 17d overdue
17612939 FUNCTIONAL RECOVERY FROM CEREBRAL INFARCTION BARRON, SEAN C 2d overdue
17906160 METHOD FOR TREATING INFLAMMATORY BOWEL DISEASE I KIM, TAEYOON 6d
18723204 METHOD OF TREATING SEVERE GRAFT VERSUS HOST DISEASE TIWARI, VYOMA SHUBHAM
18556827 METHOD FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN SPECIFIC PATIENTS USING MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS THUESON, HANNA MARIE
18556845 METHOD FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) USING MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS THUESON, HANNA MARIE
18262505 OPIOID SPARING COMPOSITIONS AND METHODS OF USING THE SAME GU, QINHUA

Top Art Units

Art UnitApps
1631 3
1638 2
1634 2
1633 1
1632 1
1653 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18723204 METHOD OF TREATING SEVERE GRAFT VERSUS HOST DISEASE TIWARI, VYOMA SHUBHAM §102§103§112 Non-Final OA Pending Jun 21, 2024
18556827 METHOD FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN SPECIFIC PATIENTS USING MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS THUESON, HANNA MARIE 1638 §102§103§112 Non-Final OA Pending Oct 23, 2023
18556845 METHOD FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) USING MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS THUESON, HANNA MARIE 1638 §103§112 Non-Final OA Pending Oct 23, 2023
18262505 OPIOID SPARING COMPOSITIONS AND METHODS OF USING THE SAME GU, QINHUA 1633 §103 Final Rejection Pending Jul 21, 2023
18041330 CELLULAR COMPOSITIONS AND METHODS OF TREATMENT MARVICH, MARIA 1634 §112DPOther Non-Final OA Pending Feb 10, 2023
18041303 A COMPOSITION COMPRISING MESENCHYMAL PRECURSOR OR STEM CELLS AND THEIR USE KIM, TAEYOON 1631 §102§103§112Other Final Rejection 18d overdue Pending Feb 10, 2023
18001462 3D CULTURE OF MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS SHIBUYA, MARK LANCE 1631 §102§103 Final Rejection 17d overdue Pending Dec 09, 2022
17906160 METHOD FOR TREATING INFLAMMATORY BOWEL DISEASE I KIM, TAEYOON 1631 §102§103§112Other Non-Final OA 6d Pending Sep 12, 2022
17906150 METHOD FOR TREATING INFLAMMATORY BOWEL DISEASE II CONNORS, ALEXANDRA F 1634 §103§112 Final Rejection Pending Sep 12, 2022
17904581 METHOD FOR TREATING CHRONIC GRAFT VERSUS HOST DISEASE TAKENAKA, RISA 1632 §103Other Non-Final OA Pending Aug 18, 2022
17612939 FUNCTIONAL RECOVERY FROM CEREBRAL INFARCTION BARRON, SEAN C 1653 §103 Non-Final OA 2d overdue Pending Nov 19, 2021

Managing Mesoblast International Sárl's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month